



Introduction and Aim

- Cancer cachexia can cause more than 20% of deaths in cancer with **sarcopenia and Quality of Life (QoL)**, independently predicting survival.
- Cachexia research suggests that biomarkers of cachexia are related to QoL and nutritional status however, the **ideal biomarker** for cachexia assessment, prognosis and blockade remains to be identified.
- **Emerging biomarkers** require baseline research of their relationships to cachexia and sarcopenia.
- The aim of the study was: i) to **establish differences** in biomarkers of cachexia, nutritional status and QoL between patients with cancer cachexia and healthy matched controls, ii) to explore the **relationships and correlations** of these markers to nutritional status and QoL.

Long-term aim: to improve knowledge of the relationships between emerging biomarkers of cancer cachexia, nutritional status and QoL so that future treatments may target cachexia and ultimately prognosis.

Methods

- Prospective case-control study: including 40 patients with advanced cancer, mixed diagnoses and 40 gender, age-matched controls.
- Nutritional status was assessed using sarcopenia [skeletal muscle index (SMI) from bioelectrical impedance] and QoL was measured using the European Organization for the Research and Treatment of Cancer Quality of Life-C30 assessment (EORTC-QLQ-C30).
- Biomarkers assessed: albumin, haemoglobin (Hb), neutrophils, lymphocytes, platelets, C-reactive protein (CRP), tumor necrosis factor alpha (TNF α), Interleukin-6 (IL-6), Interleukin-8 (IL-8), C-X-C motif chemokine ligand 5 (CXCL5) and citrullinated histone H3 (H3Cit).
- Descriptive statistics & regression analyses for correlations were undertaken, using Receiver Operator Characteristic (ROC) curve analysis to determine reference values for the group.

Results

- 43% of percent of cases were **sarcopenic** with a significantly lower SMI [6.67kg/m² (\pm 1.34) vs. 7.67kg/m² (\pm 1.08), $p < 0.01$] compared to controls (**Figure 1**).
- For all sectors of **QoL assessment**: QoL [Global Status (QL-G), Functional Scales (QL-FS) and Symptom Scales (QL-SS)] cases scored significantly different ($p < 0.01$) compared to reference values.
- Significant differences were found for albumin, lymphocytes, platelets, haemoglobin, platelet to lymphocyte ratio (PLR), systemic immune-inflammation index (SII), CRP, TNF α , all at $p < 0.01$, neutrophil to lymphocyte ratio (NLR) ($p = 0.02$), IL-6 ($p < 0.04$) and IL-8 ($p = 0.02$) between cases and controls (**Table 1**).
- No difference was found for **CXCL5** ($p = 0.22$) or **H3Cit** ($p = 0.99$) between the groups.
- **ROC curve analysis** indicated that CXCL5 (0.59) and H3Cit (0.56) ranked the lowest of all markers (**Figure 2**) while PLR, CRP and TNF α were the top ranking biomarkers with areas under the curve (AUC) of 0.84, 0.80 and 0.79 respectively.




Figure 1: Presence of sarcopenia according to Skeletal Muscle Index (SMI)




Figure 2: Receiver Operating Characteristic (ROC) curves for cut-offs: H3Cit and CXCL5

- For SMI, biomarkers that showed significance to the presence or absence of sarcopenia were albumin ($p = 0.03$), Hb ($p = 0.008$) and TNF α ($p = 0.036$) (**Figure 3**).
- Only albumin, NLR, Hb, PLR, SII, TNF α , IL-8 and CRP showed significant correlations to all three QoL sectors (**Table 2**).
- Using cut-offs for biomarkers and categories for sarcopenia CRP was significantly related to the presence and absence of sarcopenia ($p = 0.007$) (**Figure 4**).
- Using cut-offs for biomarkers and QL-FS, CXCL5 significantly correlated to QL-FS ($p = 0.04$) (**Figure 6**).

Table 1: Summary of biomarker analysis results

Marker	Reference Ranges	Cases	Controls	P-value (Cases vs. Controls)	P-value (Cases vs. Reference Constant)
Albumin (g/L)	35-50	39.66 (\pm 6.41)	46.99 (\pm 2.21)	$P < 0.01$	
Hb (g/dL)	13.8-18.8	12.38 (\pm 2.04)	15.13 (\pm 0.92)	$P < 0.01$	
NLR	2.73	4.85 (\pm 6.59)	2.31 (\pm 1.10)	$P = 0.02$	$P = 0.008$
PLR	148.82	232.90 (\pm 119.70)	119.18 (\pm 34.63)	$P < 0.01$	$P < 0.001$
SII	791.96	1387.35 (\pm 1866.47)	543.54 (\pm 301.74)	$P < 0.01$	$P = 0.051$
CRP (mg/L)	2.775	31.65 (\pm 56.54)	2.78 (\pm 6.72)	$P < 0.01$	$P = 0.002$
TNF α (pg/mL)	20.745	43.52 (\pm 52.77)	15.69 (\pm 13.51)	$P < 0.01$	$P = 0.009$
IL-6 (pg/mL)	4.39	41.13 (\pm 6.87)	35.64 (\pm 69.07)	$P = 0.04$	$P < 0.001$
IL-8 (pg/mL)	9.175	33.08 (\pm 59.90)	29.85 (\pm 81.53)	$P = 0.02$	$P = 0.023$
CXCL5 (pg/mL)	42.28	91.37 (\pm 140.30)	61.74 (\pm 59.01)	$P = 0.22$	$P = 0.033$
H3Cit (ng/mL)	1.295	2.38 (\pm 2.88)	2.38 (\pm 6.72)	$P = 0.99$	$P = 0.023$




Figure 4: CXCL5 correlations to QL-FS

Table 2: Biomarkers with significant correlations to QoL sectors

Biomarker	QoL-G	QoL-FS	QoL-SS
Albumin	+	+	-
Hb	+	+	-
NLR	-	NO SIG	+
PLR	-	-	+
SII	-	-	+
TNF α	-	-	+
IL-8	-	-	+
CRP	-	-	+




Figure 3: Biomarkers showing significance to the presence of sarcopenia

Conclusions

- CRP, albumin and haemoglobin consistently showed baseline differences between cases and controls and in further correlations to nutritional status and QoL.
- NLR, PLR, SII, TNF α , IL-6 and IL-8 showed inconsistent correlations of significance to baseline assessments.
- **Emerging biomarkers CXCL5 and H3Cit were not found to be reliable biomarkers for cancer cachexia in defining correlations to nutritional status and QoL.**